Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Significance: Synthetic nanoparticles containing either protein or peptide antigen and the immunosuppressant rapamycin are capable of inducing durable and specific resistance to mounting immune responses toward the antigen. This immunological tolerance operates on lymphocytes even after multiple immunogenic challenges with the antigen and adding enhancers of immune responses (adjuvants). As a result, the animals treated with these tolerogenic nanoparticles (tNPs) show reduced allergic hypersensitivity disorders, protection from disease relapse in a model of multiple sclerosis, and prevention of inhibitory antidrug antibody responses in an animal model of hemophilia A. These results show the potential for nanocarriers to modify the immunoreactivity of a given molecule by providing tolerogenic instructions to the immune system, thereby preventing or reversing pathological and neutralizing immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, tolerogenic rapamycin nanoparticles, but not rapamycin in free form, have been shown to be able to inhibit both cellular and humoral immune response and induce Tregs in mice (40).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [40]
Citations
Cites
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106 · cited 7×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“In fact, free rapamycin, administered at an equivalent dose as that used in tNP treatment, showed the opposite trend with respect to inhibition of OVA-specific T-cell expansion and induction of antigen-specific Tregs, perhaps due to the direct effect of free rapamycin on enhancing effector memory T-cell formation (40).”
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (1988) · Nature · doi:10.1038/334676a0 · Cited by 1,565 · cited 1×
“The transgenic BCR is specific for hen egg lysozyme (HEL), and the presence of this protein results in cell activation of MD4 B cells in vivo and in vitro (33).”
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 2×
“However, conventional therapy with free rapamycin requires chronic systemic administration, resulting in broad immunosuppression due to its direct effect on lymphocytes (28), whereas low doses of rapamycin may paradoxically augment effector T-cell memory (29).”
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594 · cited 8×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541 · cited 1×
“The codelivery of antigen and rapamycin provide an instruction set that could allow for the conditioning of tolerogenic DCs capable of inducing CD4+ Treg (22, 23).”
Self-citationUpdated assessment of the prevalence, spectrum and case definition of autoimmune disease
Hayter, S. M., & Cook, M. C. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.02.001 · Cited by 464 · cited 1×
“Clin Rev Allergy Immunol 37(2):114–124.”
Cited by
Items 301–400 of 452
Gammon, J. M., Adapa, A. R., & Jewell, C. M. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36151 · Cited by 14
The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review
Jin, S., Wan, S., Xiong, R., Li, Y., Dong, T., & Guan, C. (2024) · Inflammation Research · doi:10.1007/s00011-024-01900-w · Cited by 13
“Tolerance-induced Tregs typically require the coordinated delivery of disease-associated antigens and tolerance-inducing drugs to antigen-presenting cells [210–212].”
Current status of xenotransplantation from an immunobiological standpoint
Ko, J., Lee, G. S., Kim, H. W., Kang, M., Kim, H. J., & Park, C. (2025) · Clinical Transplantation and Research · doi:10.4285/ctr.24.0065 · Cited by 14
Immunologically Inert Nanostructures as Selective Therapeutic Tools in Inflammatory Diseases
Talamini, L., Matsuura, E., Cola, L. D., & Muller, S. (2021) · Cells · doi:10.3390/cells10030707 · Cited by 13
“The nanocarrier administration induced the inhibition of T cell activation and generation of T regulatory cells (Treg), inducing the antigen specific tolerance in autoimmune encephalomyelitis (EAE) mouse model [70].”
BackgroundNanoparticle dose and antigen loading attenuate antigen‐specific T‐cell responses
Casey, L. M., Decker, J. T., Podojil, J. R., Rad, L. M., Hughes, K. R., Rose, J. A., Pearson, R. M., Miller, S. D., & Shea, L. D. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28252 · Cited by 13
“These NPs can be further modified with immunomodulators to enhance their tolerogenic capabilities (Casey et al., 2017; Cho et al., 2017; Maldonado et al., 2015).”
BackgroundChakraborty, P., Bhattacharyya, C., Sahu, R., Dua, T. K., Kandimalla, R. J. L., & Dewanjee, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105267 · Cited by 13
Northrup, L., Griffin, J. D., Christopher, M. A., Antúnez, L. R., Hartwell, B. L., Pickens, C. J., & Berkland, C. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.034 · Cited by 13
Irvine, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0089-2 · Cited by 14
Controlling viral inflammatory lesions by rebalancing immune response patterns
Mulik, S., Berber, E., Sehrawat, S., & Rouse, B. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257192 · Cited by 13
Nachod, B. E., Thatte, A. S., Palanki, R., & Mitchell, M. J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202524097 · Cited by 12
A brief glimpse over the horizon for type 1 diabetes nanotherapeutics
Garciafigueroa, Y., Trucco, M., & Giannoukakis, N. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.016 · Cited by 13
Biomaterial-based approaches to engineering immune tolerance
Emerson, A. E., Slaby, E. M., Hiremath, S. C., & Weaver, J. D. (2020) · Biomaterials Science · doi:10.1039/d0bm01171a · Cited by 14
Yang, Y., & Santamaría, P. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.12.012 · Cited by 12
Damavandi, A. R., Mirmosayyeb, O., Ebrahimi, N., Zalpoor, H., Khalilian, P., Yahiazadeh, S., Eskandari, N., Rahdar, A., Kumar, P. S., & Pandey, S. (2022) · Applied Nanoscience · doi:10.1007/s13204-022-02698-x · Cited by 12
Wang, W., Shahzad, K. A., Li, M., Zhang, A., Zhang, L., Xu, T., Wan, X., & Shen, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00657 · Cited by 12
Self-citationChai, L.-X., Fan, X., Zuo, Y.-H., Zhang, B., Nie, G., Xie, N., Xie, Z., & Zhang, H. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213697 · Cited by 12
Therapeutic proteins immunogenicity: a peptide point of view
Real‐Fernández, F., Errante, F., Santo, A. D., Papini, A. M., & Rovero, P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00025 · Cited by 15
Size matters: Altering antigen specific immune tolerance by tuning size of particles
Li, B., Ma, L., Li, X., Suleman, Z., Liu, C., Piskareva, O., & Liu, M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.077 · Cited by 11
Advancements in nanoparticles-based therapies for biomedical applications
Lekkala, V. V. V., Reddy, M. C., Reddy, V. C., Kanthirigala, S. K., Chitta, S., Reddy, K. R., & Lomada, D. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101365 · Cited by 26
Gholamzad, M., Ebtekar, M., & Ardestani, M. S. (2017) · PubMed · Cited by 11
Consonni, A., Sharma, S., Schön, K., Lebrero‐Fernández, C., Rinaldi, E., Lycke, N. Y., & Baggi, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01133 · Cited by 11
Shi, X., Bortolussi, G., Collaud, F., Brun, P.-R. L., ten Bloemendaal, L., Guerchet, N., de Waart, D. R., Sellier, P., Duijst, S., Veron, P., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101363 · Cited by 10
“29,30 33 In preclinical models these particles proved effective in mitigating the antibody response to AAV vectors.”
Self-citationRad, L. M., Hughes, K. R., Wheeler, S. N., Decker, J. T., Orbach, S. M., Galvan, A. R., Thornhill, J., Griffin, K. V., Turkistani, H., Urie, R. R., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409852122 · Cited by 10
“Similar results have been observed with antigen encapsulating NPs in other systems ( 23 , 68 , 78 , 79 ).”
Vigario, F. L., Nagy, N. A., The, M. H., Sparrius, R., Bouwstra, J. A., Kros, A., Jiskoot, W., de Jong, E. C., & Slütter, B. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.029 · Cited by 10
Immunomodulatory Strategies for Spinal Cord Injury
Park, J. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.45.007202 · Cited by 13
“Other NPs including polystyrene [27], poly (lactic acid) [28], iron oxide [29], and gold [30] have also been employed to reprogram immune cells to modulate inflammatory responses after injury.”
BackgroundImmunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking Nanovaccine
Howard, G. P., Weidner, N. G., Khare, P., López-Gutiérrez, B., Nyasembe, V. O., Weiss, W. J., Simecka, J. W., Hamerly, T., Mao, H., & Dinglasan, R. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729086 · Cited by 10
Lau, C. Y. J., Benne, N., Lou, B., ter Braake, D., Bosman, E., van Kronenburg, N. C. H., Fens, M. H. A. M., Broere, F., Hennink, W. E., & Mastrobattista, E. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.030 · Cited by 10
Chang, Y., Xiong, W., Zou, C., Zeng, P., Hou, J., Muhitdinov, B. I., Shen, Y., Huang, Y., & Guo, S. (2023) · Small · doi:10.1002/smll.202303916 · Cited by 10
Targeting immunosuppressor cells with nanoparticles in autoimmunity: How far have we come to?
Ahmad, S., Al-Hatamleh, M. A. I., & Mohamud, R. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104412 · Cited by 10
T Cell Resistance: On the Mechanisms of T Cell Non-activation
Beckers, D., Jainarayanan, A., Dustin, M. L., & Capera, J. (2024) · Immune Network · doi:10.4110/in.2024.24.e42 · Cited by 9
“More recent efforts in the clinical field have utilised bio-degradable nanoparticles that encapsulate Ag and an immunomodulatory agent, such as rapamycin, already validated to generate tolDCs ex vivo (112).”
Jackson, M. S., Porter, L. G., & Oakes, R. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677612 · Cited by 9
“Maldonado et al. leveraged 200 nm PLGA nanoparticles co-encapsulating a myelin oligodendrocyte glycoprotein peptide epitope (MOG 35-55 35-55 ) and rapamycin, administering them intravenously to EAE mice ( 177).”
Scotland, B. L., Cottingham, A. L., Lasola, J. J., Hoag, S. W., & Pearson, R. M. (2023) · ACS Applied Polymer Materials · doi:10.1021/acsapm.3c00548 · Cited by 9
Zhu, Y., Chen, X., Zheng, H., Ma, Q., Chen, K., & Li, H. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s493374 · Cited by 10
“239 Helminth-derived molecules can be combined with anti-diabetic drugs to enhance therapeutic outcomes by modulating immune and metabolic pathways.”
New approaches in childhood IgE-mediated food allergy treatment
Gürel, D. İ., Anagnostou, A., Fiocchi, A. G., Chinthrajah, R. S., Şahiner, Ü. M., Sindher, S., & Arasi, S. (2025) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001058 · Cited by 9
Chen, K., Yang, Y., Wu, Y., Cao, W., Zhao, Y., Wang, S., & Wang, K. (2025) · Biomedical Materials · doi:10.1088/1748-605x/adbaa3 · Cited by 9
“Through TSHR-A antigen presentation, coordinated with Rapa to induce the formation of semi-mature DC, and finally form TSHR-A specific tDCs [24].”
Puentes, F., Dickhaut, K., Hofstätter, M., Pfeil, J. Q., Lauer, U., Hamann, A., Hoffmann, U., Falk, K., & Rötzschke, O. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9701-x · Cited by 10
Li, M. C., Itoh, A., Xi, J., Yu, C., Wu, Y., Ridgway, W. M., & Liu, H. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.1901301 · Cited by 9
Targeting Antigen-Presenting Cells in Multiple Sclerosis Treatment
Szpakowski, P., Ksiazek-Winiarek, D. J., & Glabinski, A. R. (2021) · Applied Sciences · doi:10.3390/app11188557 · Cited by 9
Role of Nanomaterials in COVID-19 Prevention, Diagnostics, Therapeutics, and Vaccine Development
Patel, U., Rathnayake, K., Hunt, E. C., & Singh, N. (2022) · Journal of Nanotheranostics · doi:10.3390/jnt3040011 · Cited by 9
A Question of Tolerance—Antigen-Specific Immunotherapy for Type 1 Diabetes
Naranjo, J. D. L., Bergot, A., Buckle, I., & Hamilton‐Williams, E. E. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01363-3 · Cited by 10
Najera, S. S., Nicastri, A., Bing, S. J., Sajib, A. M., Ternette, N., & Mazor, R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101506 · Cited by 9
“Therefore, identification of T cell epitopes in this protein provides valuable information for immunogenicity mitigation strategies such as peptide tolerance induction 18 and engineering next-generation enzymes with reduced immunogenicity.”
Lee, B. N., Yoo, J., Lee, H. S., & Lee, Y. H. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s558540 · Cited by 8
“12 SC and IM routes are advantageous for delivering nanomedicines to lymphatic organs such as lymph nodes, promoting immune tolerance through a process known as hyposensitization.”
Self-assembled nanoparticles of rapamycin prodrugs for the treatment of multiple sclerosis
Zhang, R., Yao, X., Li, Q., Li, X., Ma, Q., Huang, W., Hu, Y., Shi, X., Yang, Y., & Liu, H. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.12.195 · Cited by 8
Jiang, X., Wang, M., Zou, R., Fu, M., Fan, W., Wang, Y., Dai, C., Swapnil, Z., Wang, W., Wu, H., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c18354 · Cited by 9
Targeting Lymphoid Tissues to Promote Immune Tolerance
Chen, X. Y., Du, G. S., & Sun, X. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100056 · Cited by 9
Biomaterials-Based Immunomodulation of Dendritic Cells
Bracho-Sanchez, E., Lewis, J. S., & Keselowsky, B. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-18045-8_8 · Cited by 9
Griffin, J. D., Leon, M. A., Salash, J. R., Shao, M., Hartwell, B. L., Pickens, C. J., Sestak, J. O., & Berkland, C. J. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00328 · Cited by 8
Griffin, J. D., Christopher, M. A., Thati, S., Salash, J. R., Pressnall, M. M., Weerasekara, D. B., Lunte, S. M., & Berkland, C. J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00887 · Cited by 9
Pletinckx, K., Nicolson, K., Streeter, H. B., Sanderson, W. J., Schurgers, E., Jansson, L., & Wraith, D. C. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004451 · Cited by 8
Thalla, M., Kapre, S., Palakurthi, S. S., Kolimi, P., Akkireddy, R., Jyothi, V. G. S. S., Kommineni, N., Sharma, R., Kim, J. D., & Palakurthi, S. (2026) · Biomedicines · doi:10.3390/biomedicines14050964 · Cited by 8
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients.
Khalilian, S., Motovali-Bashi, M., & Rezaie, H. (2020) · PubMed Central · doi:10.22088/ijmcm.bums.9.1.33 · Cited by 8
“Such nanoparticles can contain drugs, and are delivered with the target antigen and presumably are taken up by tolerogenic APCs, and induce Tregs (120, 121).”
BackgroundInfluentialMarín, V. N., Buccini, D. F., Arboleda, J. W., Cardoso, M. H. E. S., & Franco, O. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103444 · Cited by 7
Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies
Nguyen, N. H., Jarvi, N. L., & Balu‐Iyer, S. V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.014 · Cited by 7
Biomimetic and synthetic interfaces to tune immune responses (Review)
Garapaty, A., & Champion, J. A. (2015) · Biointerphases · doi:10.1116/1.4922798 · Cited by 9
Advances in Brain Delivery Systems Based on Biomimetic Nanoparticles
Li, C., Qian, J., & Chu, Y. (2022) · ChemNanoMat · doi:10.1002/cnma.202200066 · Cited by 9
Li, S., Murakami, D., Nagatoishi, S., Liu, Y., Tsumoto, K., Katayama, Y., & Mori, T. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.06.170 · Cited by 7
Nano- and micro-based systems for immunotolerance induction in multiple sclerosis
Pires, L. R., Marques, F., Sousa, J. C., Cerqueira, J., & Pinto, I. M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1138190 · Cited by 7
“In the PLP-associated EAE model, the use of rapamycin, an immunosuppressant molecule, loaded in PLGA nanoparticles along with PLP139–151 peptide promoted complete inhibition of disease relapses after both intravenous and subcutaneous administration.(34)”
MethodAn, N. A., Yasen, G., Li, X., Shi, X., Wang, Y., & Liu, H. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c17068 · Cited by 6
Dendritic cell-based microrobots for enhanced systemic antigen-specific immune tolerance
Qin, H., Gao, J., Xu, W., Song, Y., Zhang, R., Wang, H., Ye, Y., Sun, J. T., Jiang, J., Liang, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.062 · Cited by 6
Negative Vaccination Strategies for Promotion of Transplant Tolerance
Tunbridge, M. J., Luo, X., & Thomson, A. W. (2024) · Transplantation · doi:10.1097/tp.0000000000004911 · Cited by 6
“These nanoparticles can also encapsulate immune-modifying drugs such as rapamycin 98,100,101 and be used to target myeloid cells in vivo at the time of transplant to promote tolerance.”
Screening Immunomodulators To Skew the Antigen-Specific Autoimmune Response
Northrup, L., Sullivan, B. P., Hartwell, B. L., Garza, A., & Berkland, C. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00725 · Cited by 6
Zai, K., Yuzuriha, K., Kishimura, A., Mori, T., & Katayama, Y. (2018) · Analytical Sciences · doi:10.2116/analsci.18p252 · Cited by 7
Toes, R. E. M., & Raza, K. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30445-8 · Cited by 6
Nano‐ and Microscale Drug Delivery Approaches for Therapeutic Immunomodulation
Paris, J. L., & Baeza, A. (2021) · ChemNanoMat · doi:10.1002/cnma.202100062 · Cited by 7
Decoding brain border immunity to enable future therapeutic avenues
Hoecke, L. V., Acker, L. V., & Vandenbroucke, R. E. (2026) · Trends in Immunology · doi:10.1016/j.it.2025.12.007 · Cited by 6
Designing biomaterials for the treatment of autoimmune diseases
Tang, B., Xie, X., Lu, J., Huang, W., Yang, J., Tian, J., & Lei, L. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102278 · Cited by 10
Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
Paccione, N., Rahmani, M., Barcia, E., & Negro, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010013 · Cited by 5
Salmany, N., Lotfi, H., Keyhanmanesh, ., & Ghiasi, R. (2022) · Current Women s Health Reviews · doi:10.2174/1573404818666220427083700 · Cited by 5
Baker, M., Jones, T. D., & Chamberlain, P. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch12 · Cited by 5
Proactively reducing anti-drug antibodies via immunomodulatory bioconjugation
Zhang, P., Jain, P., Tsao, C., Wu, K., & Jiang, S. (2019) · Angewandte Chemie · doi:10.1002/ange.201814275 · Cited by 4
Schiller, H. R., Zeigermann, C., & Schülke, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1748337 · Cited by 5
Bridgeman, C. J., Shah, S., Oakes, R. S., & Jewell, C. M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1184938 · Cited by 6
“Additionally, rapa encapsulation in microparticle and nanoparticle systems for antigen-specific TREG induction has been studied in multiple pre-clinical models of autoimmune diseases (Maldonado et al., 2015; Tostanoski, 2016; Gammon et al., 2023).”
MethodMiranda, M., Hansen, B. E., Wehbi, B., Porcheddu, V., van Alphen, F. P. J., Kaijen, P. H. P., Fijnvandraat, K., Lacroix‐Desmazes, S., van den Biggelaar, M., Maillère, B., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.286204 · Cited by 4
“15 re-ported that nanoparticles encapsulating rapamycin and a mixture of MHC class II-binding peptides induced specific tolerance to co-administered FVIII.”
Ming, B., Li, L., Cai, S., Hu, Z., Gao, R., Umehara, H., Zhong, J., Zheng, F., & Dong, L. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae247 · Cited by 4
Nanotechnology and biomaterials for immune modulation and monitoring
Morris, A. H., Hughes, K. R., & Shea, L. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821440-4.00001-3 · Cited by 5
Knoedler, L., Niederegger, T., Schaschinger, T., Fenske, J., Murugan, V. P. A., Knoedler, S. A., Heiland, M., Panayi, A. C., Hundeshagen, G., & Lellouch, A. G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1645261 · Cited by 3
“They were also explored for cell encapsulation and early biosensing applications aimed at protecting donor tissue and monitoring graft health (69 – 72).”
Baraf, H. S. B., Schlesinger, N., & Strand, V. (2026) · Drugs · doi:10.1007/s40265-025-02267-w · Cited by 3
Advances in nanotechnology for the diagnosis and management of autoimmune diseases
Zheng, Y., Cai, X., Zhang, L., Fei, W., Qin, D., Zhang, X., Zhu, J., Zheng, C., & Yao, Y. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101144 · Cited by 4
Ahmad, S., Aftab, M. N., & Aslam, M. (2026) · Human Immunology · doi:10.1016/j.humimm.2026.111747 · Cited by 3
Stoppelenburg, A. J., van Eden, W., van Laar, J. M., & Broere, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85831-1.00011-5 · Cited by 3
Advanced Nanovaccines for Immunotherapy Applications: From Concept to Animal Tests
Fontana, F., Figueiredo, P., & Santos, H. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815341-3.00010-9 · Cited by 4
Tsai, S. J., Kapnick, S. M., Carey, S. T., McIlvaine, R. A., Rui, Y., Eppler, H. B., Shah, S., Bridgeman, C. J., Yanes, A. A., Black, S. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.026 · Cited by 2
Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation
Chen, Y. H., Huang, H., Wang, X., Yu, X., Huang, Z., Jin, Z., Chen, C., Chen, Y., Blazar, B. R., Xu, Y., et al. (2025) · Small Science · doi:10.1002/smsc.202500481 · Cited by 2
Can parasites influence insulin signaling and development of diabetes mellitus?
Sridhar, G. R., Botta, S., & Lakshmi, G. (2026) · Academia Biology · doi:10.20935/acadbiol8088 · Cited by 2
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Delivery of Cancer Nanotherapeutics
Chung, B. L., Kaplinsky, J., Langer, R., & Kamaly, N. (2018) · Bioanalysis · doi:10.1007/978-3-030-01775-0_8 · Cited by 2
Self-citationNanovaccines delivery approaches against infectious diseases
Tabarzad, M., Mohit, E., & Ghorbani‐Bidkorbeh, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00002-6 · Cited by 2
Scotland, B. L., Dharmaraj, S., Cottingham, A. L., Truong, N., Chapoval, S. P., Keegan, A. D., & Pearson, R. M. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01632-8 · Cited by 2
“Intravenous administration of poly(lactic-co-glycolic acid)-encapsulating ovalbumin (OVA) protein (NP(OVA)) demonstrated safety and efficacy in establishing tolerance against Th2-mediated responses in a prophylactic and therapeutic murine model of allergic lung inflammation [36 ].”
Biomaterials for Engineering Immune Responses
Jhunjhunwala, S. (2018) · Journal of the Indian Institute of Science · doi:10.1007/s41745-018-0063-7 · Cited by 2
Sawaisorn, P., Tangchaikeeree, T., Polpanich, D., Midoeng, P., Udomsangpetch, R., Elaïssari, A., & Jangpatarapongsa, K. (2018) · RSC Advances · doi:10.1039/c8ra01468j · Cited by 2
Figueiredo, P., Fontana, F., & Santos, H. A. (2019) · Wiley eBooks · doi:10.1002/9783527344406.ch13 · Cited by 2
Advancements in the Field of Oral, Intravenous, and Inhaled Immunomodulators Using Nanotechnology
Verma, R., Purohit, D., Jalwal, P., Kaushik, D. K., & Pandey, P. (2022) · Springer eBooks · doi:10.1007/978-981-16-6379-6_6 · Cited by 2
Nanovaccine via Intramuscular, Subcutaneous, and Intradermal Routes
Vaghela, D. A., Pandya, M. B., Parmar, P. M., Chauhan, S. P., Vaishnav, A., Patel, R. K., Patel, D. M., Modh, V. A., & Raval, M. K. (2024) · Wiley eBooks · doi:10.1002/9781394175482.ch12 · Cited by 2
Engineering Antigen-Specific Tolerance to an Artificial Protein Hydrogel
Rapp, P. B., Baccile, J. A., Galimidi, R. P., & Vielmetter, J. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01430 · Cited by 3
Wan, X. H., Pei, W., Shahzad, K. A., Zhang, L., Song, S., Jin, X., Wang, L., Zhao, C., & Shen, C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1901408 · Cited by 2
Nanotechnology-based approaches against COVID-19
Abolmaali, S. S., Alimardani, V., Farahavar, G., Najafi, H., Shafiee, M., Tanideh, N., Tamaddon, A. M., & Ahadian, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00012-9 · Cited by 5
Biomaterials in Autoimmune Diseases
Jan, I., Rafiq, A., Ali, M., Aashaq, S., Reshi, B. A., Sheikh, F. A., Majeed, S., & Beigh, M. A. (2023) · Springer eBooks · doi:10.1007/978-981-99-2119-5_30 · Cited by 2
Li, J., Murakami, Y., Kakuta, H., Nii, T., Kishimura, A., Hase, K., Katayama, Y., & Mori, T. (2025) · NANO · doi:10.1142/s1793292025501061 · Cited by 1
Chen, H., Wu, J., Luo, J.-Y., Zheng, Q.-X., Xie, Y.-C., Liang, M., & Jiang, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c12140 · Cited by 1
Remote loading of an autoantigen in PLGA nanoparticles for the treatment of multiple sclerosis
Din, C., Xu, J., Roest, M. V., Dobson, H. E., Olsen, K. F., Kim, A., Ju, H. H., Schwendeman, A. A., Moon, J. J., & Schwendeman, S. P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114298 · Cited by 2
“Our PLGA NPs exhibit minimal burst within the first 24 h and a linear, continuous release over 56 days [22,31].”
Metadata
- Authors
- Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., Johnston, L., Farokhzad, O. C., Langer, R., Scott, D. W., von Andrian, U. H., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Uniformed Services University of the Health Sciences (US)
- Brigham and Women's Hospital (US)
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
- Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115-6017; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-12-29
- Volume
- 112
- Issue
- 2
- Pages
- E156-65
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4299193
- OpenAlex
- W2092747941
- Cited by
- 441
- References
- 48
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 31 · 2023: 36 · 2022: 45 · 2021: 42 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 50 · 2016: 24 · 2015: 23
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Juvenile Diabetes Research Foundation International (15-2011-265)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- polymeric nanoparticles, rapamycin, biodegradable nanoparticles, TLR agonists, regulatory T cells, B cell tolerance, T cell activation inhibition, experimental autoimmune encephalomyelitis, hemophilia A, factor VIII, hypersensitivity, autoimmune disease, allergy, antidrug antibodies, immunomodulation
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antigens, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Factor VIII, Female, Hemocyanins, Hemophilia A, Humans, Hypersensitivity, Delayed, Immune Tolerance, Immunosuppression Therapy, Immunosuppressive Agents, Mice, Inbred BALB C, Oligodeoxyribonucleotides, Ovalbumin, Peptide Fragments, Peptides, Polyglycolic Acid, Proteins, Recombinant Proteins, CD4-Positive T-Lymphocytes, Lactic Acid, Sirolimus, Mice, Nanoparticles, Nanocapsules, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.